Bangor

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• COPD2 trials

Phase

• Phase 33 trials
• Phase 41 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• GlaxoSmithKline4 trials

Running trials

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· GlaxoSmithKline· Source

  Contact: Paul Shapero (principal investigator)

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  NCT06961214· Phase 3· GlaxoSmithKline· Source

  Contact: Paul Shapero (principal investigator)

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD2 recruiting

Closed trials

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source